HK1205198A1 - 抑制劑治療響應的預測 - Google Patents

抑制劑治療響應的預測

Info

Publication number
HK1205198A1
HK1205198A1 HK15105427.5A HK15105427A HK1205198A1 HK 1205198 A1 HK1205198 A1 HK 1205198A1 HK 15105427 A HK15105427 A HK 15105427A HK 1205198 A1 HK1205198 A1 HK 1205198A1
Authority
HK
Hong Kong
Prior art keywords
jak
stat
prediction
treatment response
inhibitor
Prior art date
Application number
HK15105427.5A
Other languages
English (en)
Inventor
Alexander Cao
Michael Morrissey
Dmitriy Sonkin
Michael Palmer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1205198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1205198A1 publication Critical patent/HK1205198A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15105427.5A 2012-07-27 2015-06-08 抑制劑治療響應的預測 HK1205198A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US201361829327P 2013-05-31 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Publications (1)

Publication Number Publication Date
HK1205198A1 true HK1205198A1 (zh) 2015-12-11

Family

ID=48906529

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105427.5A HK1205198A1 (zh) 2012-07-27 2015-06-08 抑制劑治療響應的預測

Country Status (18)

Country Link
US (1) US20150299796A1 (zh)
EP (1) EP2877596A1 (zh)
JP (1) JP2015526074A (zh)
KR (1) KR20150038241A (zh)
CN (1) CN104508149A (zh)
AU (2) AU2013295855A1 (zh)
BR (1) BR112015001521A2 (zh)
CA (1) CA2880198A1 (zh)
CL (1) CL2015000192A1 (zh)
HK (1) HK1205198A1 (zh)
IL (1) IL236897A0 (zh)
MX (1) MX2015001269A (zh)
PH (1) PH12015500169A1 (zh)
RU (1) RU2015106714A (zh)
SG (1) SG11201500261VA (zh)
TN (1) TN2015000019A1 (zh)
TW (1) TW201409030A (zh)
WO (1) WO2014018632A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US20060194275A1 (en) * 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
JP2012506238A (ja) * 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
NZ611654A (en) * 2010-12-03 2015-08-28 Ym Biosciences Australia Pty Treatment of jak2-mediated conditions

Also Published As

Publication number Publication date
SG11201500261VA (en) 2015-02-27
AU2013295855A1 (en) 2015-02-12
JP2015526074A (ja) 2015-09-10
TW201409030A (zh) 2014-03-01
IL236897A0 (en) 2015-03-31
AU2017204894A1 (en) 2017-08-03
WO2014018632A1 (en) 2014-01-30
BR112015001521A2 (pt) 2017-11-07
CA2880198A1 (en) 2014-01-30
CL2015000192A1 (es) 2015-06-26
US20150299796A1 (en) 2015-10-22
MX2015001269A (es) 2015-05-08
EP2877596A1 (en) 2015-06-03
PH12015500169A1 (en) 2015-03-16
CN104508149A (zh) 2015-04-08
RU2015106714A (ru) 2016-09-20
TN2015000019A1 (en) 2016-06-29
KR20150038241A (ko) 2015-04-08

Similar Documents

Publication Publication Date Title
IL255045A0 (en) A crystal of flumioxazin
HK1205198A1 (zh) 抑制劑治療響應的預測
IL287057A (en) Purified iduronate-2-sulfatase
EP2822897A4 (en) TREATMENT OF INDUSTRIAL WATER SYSTEMS
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
SG10201510800PA (en) Purification of flaviviruses
EP2867792A4 (en) ACHIEVING PREDICTED ACTIONS
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
EP2709665A4 (en) TREATMENT OF PSORIASIS
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
EP2892529A4 (en) USES OF (-) - PERHEXILINE
HK1210937A1 (zh) 匹多莫德治療銀屑病的用途
IL259184A (en) Crystal of flumeoxazine
ZA201500297B (en) Prediction of treatment response to jak/stat inhibitor
GB201212717D0 (en) Treatment of musculoskeletal conditions
TWM433525U (en) Structure of calorifier